ABBOTT INFORMATICS HELPS LABS AND HEALTHCARE SETTINGS WITH COVID-19 TESTING AND REPORTING

Our presence in public and private sectors

STARLIMS Solution is used in 27 Public Health U.S. state labs, various cities and counties in the U.S. and overseas. The CDC uses STARLIMS in 60 of their 90 labs.

We also partner with APHL to facilitate automated COVID-19 Public Health reporting per CARES Act Section 18115.

In private laboratories STARLIMS addresses the needs for COVID-19 testing, to help them provide a safe environment and sustain operational continuity.

STARLIMS ALLOWS LABORATORIES TO...

Execute rapid deployment of COVID-19 testing to comply with Public Health reporting laws

Streamline Sample Collection & Test Ordering

STARLIMS Portal & Mobile Solutions. LIMS with API and HL7 integration to external ordering systems

Automated Instrument Interfaces

Easy to configure bi-directional interfaces with various instruments

Support for Simple & Pool Testing Workflows

Workflow engine to configure simple and complex workflows such as pooling

Automated Public Health Reporting

Validated with APHL HL7 interfaces to report automatically within 24 hours

STARLIMS ALLOWS LABORATORIES TO...

Provide Digital Solutions for COVID-19 Testing with ID NOW in the U.S.

STARLIMS Digital Solution collects patient demographics, ordering physician information, and questions for Covid-19 testing. STARLIMS Digital Solution then retrieves patient test results from ID Now via RALSLiNK and reports the consolidated Covid-19 patient testing data to Public Health authorities within 24 hours.

STARLIMS REPORTS TO PUBLIC HEALTH AUTHORITIES

Compliance with CARES Act Section 18115 in the U.S.

STARLIMS provides an HL7 configurable interface, validated in partnership with APHL, to ensure automated reporting to Public Health state authorities based on the individual's residence.

Reporting through the STARLIMS APHL AIMS Platform interface allows laboratories to be compliant with CARES Act reporting requirements, and avoid potential civil monetary penalties for non-compliance.[1]

1. CMS Interim Final Rule (https://www.cms.gov/files/document/covid-ifc-3-8-25-20.pdf)

The ID NOW™ COVID-19 EUA has not been FDA cleared or approved. It has been authorized by the FDA under an emergency use authorization for use by authorized laboratories and patient care settings. The test has been authorized only for the detection of nucleic acid from SARS-CoV-2, not for any other viruses or pathogens, and is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostic tests for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Act, 21 U.S.C. § 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner.

2020.PH.35-1

Abbott